The four categories of WGS in 2026, and why you should care which one you're buying
Until 2024 the consumer whole genome sequencing question was essentially "which lab do I send my spit to?" In 2026 that's the wrong question, because the market has split into four fundamentally different product categories that deserve to be evaluated separately.
Category one — mainstream health WGS — is what most readers picture when they think about sending DNA in the mail. A 30× whole-genome read, a consumer app with health reports, ancestry, pharmacogenomics, and a 4-to-10 week turnaround. Nucleus, Sequencing.com, SelfDecode, tellmeGen, and DNA Complete all live here. The competition is on report depth, app polish, delivery speed, and increasingly on partnerships (Nucleus' Illumina NovaSeq X Plus arrangement is the cleanest public example).
Category two — clinical, prescription-mediated WGS — looks superficially like the same product but is built for a fundamentally different reader. Veritas Genetics' myGenome is the only clear example in April 2026. You need a prescription (Veritas will issue one via their own telegenetics consult), the turnaround is 12–16 weeks, and the price is a premium $599 — but the price includes a pre-test and post-test genetic counselor session, both substantive, and the report is formatted for a physician to act on. This is preventive medicine in a $599 box; it's not the right product for a reader who just wants to know their ancestry.
Category three — genealogy-first WGS — collapsed and expanded at the same time this cycle. Full Genomes and YSEQ were there already, serving the serious enthusiast market. MyHeritage's October 2025 move to low-pass WGS (via an Ultima Genomics partnership) is the big new entrant: a whole-genome sequence at a $89 genealogy-kit price, optimized for family-history matching rather than clinical-grade variant calling. The key thing to understand about LP-WGS: it is NOT a cheaper 30× WGS. It is a different product. Buy MyHeritage for genealogy; do not buy it expecting clinical insights.
Category four — interpretation-only add-ons — is the smallest bucket but increasingly important as more people accumulate raw data from multiple providers. Genomapp is the leading example: it does no sequencing at all, reads the raw VCF or BAM from whoever sequenced you, and produces ~300 panels of analysis for $15. It's a natural companion to any of the three lab categories, not a substitute for any of them.
If you're buying in April 2026, step one is to identify your category, not pick a company. If you want comprehensive health insights, compare within mainstream health. If you want clinical-grade results you can hand to a physician, go straight to category two and ignore consumer pricing entirely. If you're after ancestry, the newest tool in the box — MyHeritage's LP-WGS — changed the math, and category three is where to look. And interpretation add-ons belong on top of whichever lab you picked, not instead of it.